

## Remuneration report 2024

### Introduction

This report describes how the guidelines for executive remuneration of Swedish Orphan Biovitrum AB (publ), (Sobi™) (Reg. No. 556038-9321) (the “Company” or “Sobi”) (the “remuneration guidelines”), adopted by the Annual General Meeting 2020 and 2024, were applied in 2024. The report also provides information on remuneration to the CEO and the deputy CEO. In addition, the report provides a summary of the Company’s outstanding long-term incentive programmes. The report has been prepared in accordance with the Swedish Companies Act (2005:551) and the Rules on Remuneration of the Board and Executive Management and on Incentive Programmes issued by the Swedish Corporate Governance Board and administered by the Stock Market Self-Regulation Committee.

Further information on executive remuneration is available in note 10 (Employees, personnel costs and remuneration of board members and senior executives) on pages 105-112 in the annual report 2024.

Information on the work of the remuneration committee in 2024 is set out in the corporate governance report available on pages 141-150 in the annual report 2024.

Fees to the Board of Directors are not covered by this report. Such fees are resolved annually by the Annual General Meeting and disclosed in note 10 on page 108 in the annual report 2024.

The members of the Board of Directors elected by the general meeting may receive consultancy fees for services provided to the Company. Such services must contribute to the Company’s business strategy and long-term interests, including its sustainability, and may not relate to regular board work. Any consultancy fee shall be based on market terms and may for each member of the Board of Directors not exceed the annual remuneration for the board assignment. The above applies correspondingly to services performed by a wholly-owned company of a member of the Board of Directors. During 2024, board member Anders Ullman, through his company Anders Ullman Consulting AB, has performed consulting services for the Company and received consultancy fees of a total of kSEK 465. The

purpose of the consultancy assignment was to support the Company in setting up a Scientific Advisory Board. It has been considered necessary and beneficial to the Company to procure the services, for which fees on market terms have been paid.

### Key developments 2024

The CEO summarises the Company’s overall performance in his statement on page 8 in the annual report 2024.

### The Company’s remuneration guidelines: scope, purpose and deviations

A prerequisite for the successful implementation of the Company’s business strategy and safeguarding of its long-term interests, including its sustainability, is that the Company is able to recruit and retain highly qualified personnel. As an international company, a majority of Sobi’s personnel is employed outside of Sweden. Remuneration for the Executive Committee is based on a total remuneration approach. The position of total remuneration should be market competitive relative to competitors in each local market. The remuneration guidelines shall enable international hiring and support diversity within the Executive Committee.

Under the remuneration guidelines, the remuneration shall be on market terms and may consist of the following components: fixed base pay, variable pay, pension benefits and other benefits. The guidelines are found on pages 68-70 in the annual report 2023 and on pages 106-107 in the annual report 2024. During 2024, the Company has complied with the applicable remuneration guidelines adopted by the general meeting. No derogations or deviations have been made from the remuneration guidelines or from the decision-making process which, pursuant to the guidelines, is to be applied in order to set remuneration. The auditor’s report regarding the Company’s compliance with the guidelines is available on [www.sobi.com/en/governance](http://www.sobi.com/en/governance). No remuneration has been reclaimed. In addition to remuneration covered by the remuneration guidelines, the Annual General Meetings of the Company have resolved to implement long-term incentive programmes.

Tables 1(1) and 1(2) – Total remuneration of the CEO and the deputy CEO, respectively, in 2024 (kSEK)<sup>1)</sup>

Name of director (position)	1 Fixed remuneration		2 Variable remuneration		3 Extraordinary items	4 Pension expense	5 Total remuneration	6 Proportion of fixed and variable remuneration <sup>5)</sup>
	Base salary <sup>2)</sup>	Other benefits <sup>3)</sup>	One-year variable	Multi-year variable <sup>4)</sup>				
Guido Oelkers (CEO)	13,612	2	11,382	88,199	0	4,747	117,942	Fixed: 16% Variable: 84%

<sup>1)</sup> Except for multi-year variable remuneration, the table reports remuneration earned in 2024. Multi-year variable remuneration is reported if vested in 2024, as set out in column 10 of Table 2 and column 8 of Table 3 below (as applicable). Disbursement of any payments may or may not have been made the same year.

<sup>2)</sup> Including vacation allowance, car allowance, and compensation for social security contributions when transitioning from one system to another.

<sup>3)</sup> Including benefits provided for meals.

<sup>4)</sup> Vesting of shares and options under long-term incentive program 2021. Vesting period of three years (1 June 2021–1 June 2024). Calculated as the sum of the market price per share at vesting (SEK 280.2) multiplied by the number of shares vested, and the difference between the market price per share at the start of the exercise period (SEK 282.00) and the strike price per option (SEK 146.13) multiplied by the number of options vested. The value at vesting is not to be equated to the year’s cost for Sobi presented in the annual report 2024.

<sup>5)</sup> Pension expense, which is expressed as a percentage of base salary, has been counted entirely as fixed remuneration.

Name of director (position)	1 Fixed remuneration		2 Variable remuneration		3 Extraordinary items	4 Pension expense	5 Total remuneration	6 Proportion of fixed and variable remuneration <sup>5)</sup>
	Base salary <sup>2)</sup>	Other benefits <sup>3)</sup>	One-year variable	Multi-year variable <sup>4)</sup>				
Henrik Stenqvist (deputy CEO)	5,065	172	2,707	19,426	0	1,284	28,654	Fixed: 23% Variable: 77%

<sup>1)</sup> Except for multi-year variable remuneration, the table reports remuneration earned in 2024. Multi-year variable remuneration is reported if vested in 2024, as set out in column 10 of Table 2 and column 8 of Table 3 below (as applicable). Disbursement of any payments may or may not have been made the same year.

<sup>2)</sup> Including vacation allowance.

<sup>3)</sup> Including benefits provided for meals, company car, fuel, and medical insurance.

<sup>4)</sup> Vesting of shares and options under long-term incentive program 2021. Vesting period of three years (1 June 2021–1 June 2024). Calculated as the sum of the market price per share at vesting (SEK 280.2) multiplied by the number of shares vested, and the difference between the market price per share at the start of the exercise period (SEK 282.00) and the strike price per option (SEK 146.13) multiplied by the number of options vested. The value at vesting is not to be equated to the year’s cost for Sobi presented in the annual report 2024.

<sup>5)</sup> Pension expense, which is defined contribution, has been counted entirely as fixed remuneration.

### Share-based remuneration

#### Share-related and share price-related incentive plans

The Company’s Annual General Meeting has adopted the long-term incentive programmes (“LTIP”) that currently are outstanding (LTIP 2022, LTIP 2023 and LTIP 2024). LTIP 2021

vested in 2024. All programmes run for three years. The aim has been to create long-term commitment to the Company, to offer participants the opportunity to share in the Company’s long-term success and value creation, and to enable the Company to attract and retain senior executives and senior managers. Each of the 2021–2024 LTIPs has two sub-programmes: (i) the Management Programme covering the CEO, senior executives (including the deputy CEO) and managers, and (ii) the Employee Programme.

The 2021–2024 LTIPs are structured according to similar principles.

- The programmes have a three-year vesting period.
- The Employee Programmes require a personal investment in Sobi shares, and matching shares may be allotted free of consideration.
- The Management Programmes do not require a personal investment in Sobi shares, and no matching shares are allotted. Instead, under the Management Programmes, performance shares may be allotted if the programme criteria are met. The CEO and other members of the Executive Committee (including the deputy CEO) are recommended to accumulate a personal holding in Sobi shares.
- The number of performance shares that employees are entitled to receive differs according to the organisational level.
- One requirement for all programmes is that the employee must, as a general rule, be permanently employed throughout the entire vesting period and, in relation to the Employee Programmes, investment shares must be retained throughout the entire vesting period.
- The performance targets for the Management Programmes are that the share price increases (as adjusted for any dividends: absolute Total Shareholder Return (TSR)) by a certain rate over a three-year period (60% weight). In order for any vesting related to absolute TSR increase to occur, the TSR must increase by more than 10% over the vesting period. In order for full vesting related to absolute TSR increase to occur, the TSR must increase by at least 40% over the vesting period. If the TSR increase is between 10% and 40%, a linear vesting related to absolute TSR increase will occur. Furthermore, the actual annual revenues over a three-year period must meet or exceed the Sobi Group's target annual revenues for the Management Programme as set by the Board of Directors each year (40% weight). If the threshold is reached or exceeded for a financial year, full vesting related to annual revenues in respect of that financial year will occur (i.e., 1/3 of 40%). If the threshold is not reached for a financial year, no vesting related to annual revenues in respect of that financial year will occur.

In addition to the possibility to be allocated a number of performance shares, the CEO, other members of the Executive Committee (including the deputy CEO) and a limited number of key individuals in the Company have been granted a number of employee stock options under the Management Programmes of the 2021–2024 LTIPs (the "**Option Programmes**"). Subject to the satisfaction of the performance target (actual average revenues must meet or exceed the Sobi Group's average target revenues for the Management Programme as set by the Board of Directors each year over a three-year period) and other programme criteria, each option entitles the holder to acquire one Sobi common share ("**Option Share**") at a strike price equivalent to 105 % of the volume-weighted average price paid for the Sobi common share at Nasdaq Stockholm, adjusted for any dividend payments, during a period of ten trading days in connection with the commencement of the vesting period. The value of each Option Share received upon exercise of options is capped to three times the strike price in the Option Programmes, meaning that the

number of shares delivered to the participant upon exercise of options may be reduced. The vesting periods of the Option Programmes are three years, followed by a two-year exercise period.

For employees in the US and Canada, the Company has three outstanding cash-based programmes (2022–2024) and had one cash-based programme that vested in 2024 ("**North America Cash-Based Programmes**"). The North America Cash-Based Programmes 2021–2024 have three-year vesting periods. Each of the North America Cash-Based Programmes consists of two components: a time-based component (50% weight) and a performance-based component (50% weight) based on two performance targets. For the North America Cash-Based Programmes 2021–2022, the first performance target (50% weight of the performance-based component) is that the TSR must increase by at least 10% over the vesting period, and for the North America Cash-Based Programmes 2023–2024 the first performance target (50% weight of the performance-based component) is that the corporate actual annual revenues must reach or exceed the target annual revenues for the Management Program set for each financial year. The second performance target for the North America Cash-Based Programmes 2021–2024 (50% weight of the performance-based component) is that sales in North America shall amount to at least 95% in relation to the target over the vesting period. The Company also has one outstanding cash-based programme for employees in China and Japan (2022) and had one cash-based programme that vested in 2024 ("**Asia Cash Based Programmes**"). The Asia Cash-Based Programmes 2021–2022 have three-year vesting periods and consist of two components: a time-based component (50% weight) and a performance-based component (50% weight) based on two performance targets. The first performance target (60% weight of the performance-based component) is that the TSR must increase by 10% to 40% over the vesting period. There is no payment below 10% and a linear payment for 10% to 40%. The second performance target (40% weight of the performance-based component) is that the actual annual revenues during the three-year period must reach or exceed the target for the annual revenues. These programs do not include any members of the Executive Committee.

Further information on share-related and share price-related incentive plans is available in note 10 (Employees, personnel costs and remuneration of board members and senior executives) on pages 105–112 in the annual report 2024.

On 22 August 2023, the Board of Directors of Sobi resolved on an issue of ordinary shares with preferential rights for shareholders of Sobi. As a result of the share issue, a recalculation was made of the number of performance shares, matching shares, options, and the exercise prices of the options under the then outstanding long-term incentive programmes. The recalculation was based on the rules of Nasdaq Stockholm AB's Exchange Rules and Clearing Rules for Nasdaq Derivatives Markets, using the Ratio Method, which represents Swedish market practice as set out in the terms and conditions of the programmes. The 2021–2023 LTIPs were adjusted with a ratio of 1.0471, which in total increased the volume of such incentive programmes by 163,226 shares and 287,646 options.

Tables 2–3 below set forth information on relevant share and option-based programmes granted or offered to the CEO and the deputy CEO (including the main conditions for exercising the rights under such programmes).

Table 2 – Option Programmes

Name of director (position)	The main conditions of share option plans							Information regarding the reported financial year					
	1 Name of plan	2 Performance period	3 Award date	4 Vesting date	5 End of retention period	6 Exercise period	7 Exercise price (SEK)	Opening balance	During the year		Closing balance		
								8 Options held at beginning of year	9 Options awarded	10 Options vested	11 Options subject to performance condition	12 Options awarded and unvested	13 Options subject to retention period
Guido Oelkers (CEO)	2021 Option Programme	2021-2023	2021-06-01	2024-06-01	2024-06-01	2024-06-02 2026-06-02	146.13	436,378	0	436,378 <sup>1)</sup>	0	0	0
	2022 Option Programme	2022-2024	2022-05-30	2025-05-30	2025-05-30	2025-05-31 2027-05-31	208.11	304,616	0	0	304,616	0	0
	2023 Option Programme	2023-2025	2023-06-07	2026-06-07	2026-06-07	2026-06-08 2028-06-08	235.15	279,208	0	0	279,208	0	0
	2024 Option Programme	2024-2026	2024-05-23	2027-05-23	2027-05-23	2027-05-24 2029-05-24	296.04	0	254,305 <sup>2)</sup>	0	254,305	0	0
<b>Total</b>							<b>1,020,202</b>	<b>254,305</b>	<b>436,378</b>	<b>838,129</b>	<b>0</b>	<b>0</b>	
Henrik Stenqvist (deputy CEO)	2021 Option Programme	2021-2023	2021-06-01	2024-06-01	2024-06-01	2024-06-02 2026-06-02	146.13	96,111	0	96,111 <sup>1)</sup>	0	0	0
	2022 Option Programme	2022-2024	2022-05-30	2025-05-30	2025-05-30	2025-05-31 2027-05-31	208.11	65,835	0	0	65,835	0	0
	2023 Option Programme	2023-2025	2023-06-07	2026-06-07	2026-06-07	2026-06-08 2028-06-08	235.15	57,232	0	0	57,232	0	0
	2024 Option Programme	2024-2026	2024-05-23	2027-05-23	2027-05-23	2027-05-24 2029-05-24	296.04	0	49,297 <sup>3)</sup>	0	49,297	0	0
<b>Total</b>							<b>219,178</b>	<b>49,297</b>	<b>96,111</b>	<b>172,364</b>	<b>0</b>	<b>0</b>	

<sup>1)</sup> Value at vesting: kSEK 59,291, calculated as the difference between the market price per share at the start of the exercise period (SEK 282.00) and the strike price per option (SEK 146.13) multiplied by the number of options vested. The value at vesting is not to be equated to the year's cost for Sobi presented in the annual report 2024.

<sup>2)</sup> The aggregate market value of the options at the time of award, based on a Black & Scholes valuation method, was kSEK 16,537. The exercise of the options is subject to performance targets (actual average revenues meeting or exceeding the Sobi Group's average target revenues for the Management Programme as set by the Board of Directors each year over a three-year period). The aggregate market value of the underlying shares at the time of the award was kSEK 71,701. At the time of award, the aggregate price to exercise the options was kSEK 75,284.

<sup>3)</sup> Value at vesting: kSEK 13,059, calculated as the difference between the market price per share at the start of the exercise period (SEK 282.00) and the strike price per option (SEK 146.13) multiplied by the number of options vested. The value at vesting is not to be equated to the year's cost for Sobi presented in the annual report 2024.

<sup>4)</sup> The aggregate market value of the options at the time of award, based on a Black & Scholes valuation method, was kSEK 3,206. The exercise of the options is subject to performance targets (actual average revenues meeting or exceeding the Sobi Group's average target revenues for the Management Programme as set by the Board of Directors each year over a three-year period). The aggregate market value of the underlying shares at the time of the award was kSEK 13,899. At the time of the award, the aggregate price to exercise the options was kSEK 14,594.

Table 3 – LTIP

Name of director (position)	The main conditions of share award plans						Information regarding the reported financial year					
	1 Name of plan	2 Performance period	3 Award date	4 Vesting date	5 End of retention period	6 Share awards held at beginning of year <sup>1)</sup>	Opening balance	During the year		Closing balance		
							7 Awarded	8 Vested	9 Subject to performance condition	10 Awarded and unvested at year end <sup>2)</sup>	11 Shares subject to retention period	
Guido Oelkers (CEO)	2021 Share Programme	TSR: 2021-06-01 - 2024-06-01 Annual revenues (each year): 2021 - 2023	2021-06-01	2024-06-01	2024-06-01	103,169	0	103,169 <sup>2)</sup>	0	0	0	0
	2022 Share Programme	TSR: 2022-05-30 - 2025-05-30 Annual revenues (each year): 2022 - 2024	2022-05-30	2025-05-30	2025-05-30	77,514	0	0	46,508	31,006	0	0
	2023 Share Programme	TSR: 2023-06-07 - 2026-06-07 Annual revenues (each year): 2023 - 2025	2023-06-07	2026-06-07	2026-06-07	78,086	0	0	57,263	20,823	0	0
	2024 Share Programme	TSR: 2024-05-23 - 2027-05-23 Annual revenues (each year): 2024 - 2026	2024-05-23	2027-05-23	2027-05-23	0	66,214	0	57,385	8,829	0	0
<b>Total</b>						<b>258,769</b>	<b>66,214</b>	<b>103,169</b>	<b>161,156</b>	<b>60,658</b>	<b>0</b>	
Henrik Stenqvist (deputy CEO)	2021 Share Programme	TSR: 2021-06-01 - 2024-06-01 Annual revenues (each year): 2021 - 2023	2021-06-01	2024-06-01	2024-06-01	22,723	0	22,723 <sup>3)</sup>	0	0	0	0
	2022 Share Programme	TSR: 2022-05-30 - 2025-05-30 Annual revenues (each year): 2022 - 2024	2022-05-30	2025-05-30	2025-05-30	16,755	0	0	10,053	6,702	0	0
	2023 Share Programme	TSR: 2023-06-07 - 2026-06-07 Annual revenues (each year): 2023 - 2025	2023-06-07	2026-06-07	2026-06-07	15,422	0	0	11,309	4,113	0	0
	2024 Share Programme	TSR: 2024-05-23 - 2027-05-23 Annual revenues (each year): 2024 - 2026	2024-05-23	2027-05-23	2027-05-23	0	12,837	0	11,125	1,712	0	0
<b>Total</b>						<b>54,900</b>	<b>12,837</b>	<b>22,723</b>	<b>32,487</b>	<b>12,527</b>	<b>0</b>	

<sup>1)</sup> Refers to the maximum number of shares at the award date subject to performance conditions under the respective performance periods.

<sup>2)</sup> Value at vesting: kSEK 28,908, calculated as the market price per share at vesting (SEK 280.2) multiplied by the number of shares vested, 103,169. The value at vesting is not to be equated to the year's cost for Sobi presented in the annual report 2024.

<sup>3)</sup> Value at vesting: kSEK 6,367, calculated as the market price per share at vesting (SEK 280.2) multiplied by the number of shares vested, 22,723. The value at vesting is not to be equated to the year's cost for Sobi presented in the annual report 2024.

<sup>4)</sup> Refers to shares awarded which were subject to achieved targets with regards to annual revenues. The shares will not be allotted until after the respective vesting date.

### Application of performance criteria

The performance measures for the variable remuneration of the CEO and the deputy CEO have been selected for the promotion of the Company's business strategy, long-term development including its sustainability, value creation and financial growth and have been designed in a way that encourages compliant behaviour.

Set out below is a description of how the criteria for payment of variable short- and long-term compensation have been applied during the financial year.

### Performance of the CEO and the deputy CEO in the reported financial year: short term variable cash remuneration

As to the short-term variable remuneration ("STI"), the Board of Directors has made both quantitative and qualitative assessments. This has involved the application of judgement and discretion to ensure that the outcome will reflect broader considerations and remain appropriate and proportionate, in

addition to the formulaic outcome on the basis of scorecards. Accordingly, the short-term variable cash remuneration for the financial year 2024 was determined by both financial and non-financial performance criteria. The financial performance criteria consisted of annual revenue (relative weighting 52.5%) and EBITA (relative weighting 22.5%). The non-financial performance criteria were selected based on strategic objectives as well as short-term and long-term business development goals for 2024 (relative weighting 25%).

The evaluation of the performance criteria resulted in a remuneration outcome for the CEO Guido Oelkers amounting to kSEK 11,382, whereof kSEK 5,593 is related to annual revenue, kSEK 2,745 to EBITA and kSEK 3,043 to the non-financial objectives. For the deputy CEO Henrik Stenqvist, the evaluation of the performance criteria resulted in a remuneration outcome amounting to kSEK 2,707, whereof kSEK 1,330 is related to annual revenue, kSEK 653 to EBITA and kSEK 724 to the non-financial objectives.<sup>1</sup>

**Table 4 – Performance of the CEO and the deputy CEO in the reported financial year: share-based incentives<sup>1</sup>**

Name of director (position)	Name of plan	Description of the criteria related to the remuneration component	Relative weighting of the performance criteria	3	
				a) Measured performance and	b) actual award/ remuneration outcome
Guido Oelkers (CEO)	2021 Share Programme	Absolute TSR increase 2021-06-01 - 2024-06-01	60%	a) 91.16% <sup>21</sup>	b) kSEK 17,233
		Annual Revenues 2021 - 2023	40%	N/A <sup>31</sup>	
	2021 Option Programme	Average Annual Revenues 2021-2023	100%	a) MSEK 22,412	b) kSEK 59,291 <sup>41</sup>
		Absolute TSR increase 2022-05-30 - 2025-05-30	60%	N/A <sup>61</sup>	
	2022 Share Programme	Annual Revenues 2022 - 2024	40%	a) MSEK 26,323	b) kSEK 3,280 <sup>51</sup>
		Absolute TSR increase 2023-06-07 - 2026-06-07	60%	N/A <sup>61</sup>	
	2023 Share Programme	Annual Revenues 2023 - 2025	40%	a) MSEK 26,323	b) kSEK 3,304 <sup>51</sup>
		Absolute TSR increase 2024-05-23 - 2027-05-23	60%	N/A <sup>61</sup>	
	2024 Share Programme	Annual Revenues 2024 - 2026	40%	a) MSEK 26,323	b) kSEK 2,802 <sup>51</sup>
		Absolute TSR increase 2021-06-01 - 2024-06-01	60%	a) 91.16% <sup>21</sup>	b) kSEK 3,796
Henrik Stenqvist (deputy CEO)	2021 Share Programme	Annual Revenues 2021 - 2023	40%	N/A <sup>31</sup>	
		Average Annual Revenues 2021-2023	100%	a) MSEK 22,412	b) kSEK 13,059 <sup>41</sup>
	2022 Share Programme	Absolute TSR increase 2022-05-30 - 2025-05-30	60%	N/A <sup>61</sup>	
		Annual Revenues 2022 - 2024	40%	a) MSEK 26,323	b) kSEK 709 <sup>51</sup>
	2023 Share Programme	Absolute TSR increase 2023-06-07 - 2026-06-07	60%	N/A <sup>61</sup>	
		Annual Revenues 2023 - 2025	40%	a) MSEK 26,323	b) kSEK 653 <sup>51</sup>
	2024 Share Programme	Absolute TSR increase 2024-05-23 - 2027-05-23	60%	N/A <sup>61</sup>	
		Annual Revenues 2024 - 2026	40%	a) MSEK 26,323	b) kSEK 543 <sup>51</sup>

<sup>1</sup> Any right to exercise the options under the Option Programmes requires that the actual average revenues meet or exceed the Sobi Group's average target revenues for the Management Programmes as set by the Board of Directors each year over a three-year period. The outcome of the 2022–2024 Option Programmes will be concluded in 2025, 2026 and 2027, respectively. These Option Programmes are therefore not included in Table 4.

<sup>21</sup> The Absolute TSR increase corresponds to approximately 100% of the maximum possible vesting related to this target for the 2021 Share Programme. The value at vesting is not to be equated to the year's cost for Sobi presented in the annual report 2024. Total vesting under the 2021 Share Programme is presented in table 3 column 8.

<sup>31</sup> Annual Revenues were measured during 2021, 2022 and 2023 and were fully achieved, total vesting under the 2021 Share Programme is presented in table 3 column 8.

<sup>41</sup> Vesting of options under long-term incentive program 2021. Calculated as the difference between the market price per share at the start of the exercise period (SEK 282.00) and the strike price per option (SEK 146.13) multiplied by the number of options vested. The value at vesting is not to be equated to the year's cost for Sobi presented in the annual report 2024.

<sup>51</sup> Annual Revenues for the performance year 2024 at fixed rates, equivalent information for previous performance years is presented in each respective remuneration report. Based on market price per share at balance date 30 December 2024 (SEK 317.40) multiplied by the number of shares vested. Vesting period still running, and the shares will not be allotted until after the respective vesting date. The value at balance date, 30 December 2024, is not to be equated to the year's cost for Sobi presented in the annual report 2024.

<sup>61</sup> Performance period still running.

<sup>1</sup> The financial targets for STI are calculated at fixed rates (equals 2024 target exchange rates). Annual Revenues for 2024 at fixed rates was MSEK 26,323 and adjusted EBITA for 2024 at fixed rates was MSEK 9,607.

Comparative information on remuneration and the Company's performance

**Table 5 – Remuneration of the CEO and deputy CEO compared with the Company's performance and remuneration of other employees**

Total Remuneration CEO and deputy CEO (kSEK)	RFY 2020	RFY 2021	RFY 2022	RFY 2023	RFY 2024
Guido Oelkers (CEO)	55,571	31,564 (-43%)	43,000 (+36%)	34,244 (-20%)	117,942 (+244%) <sup>1)</sup>
Henrik Stenqvist (deputy CEO)	7,617	9,703 (+27%)	12,847 (+32%)	10,261 (-20%)	28,654 (+179%) <sup>2)</sup>
<b>Company's Performance (MSEK)</b>					
Total Revenue	15,261	15,529 (+2%)	18,790 (+21%)	22,123 (+18%)	26,027 (+18%)
EBITA <sup>3)</sup>	6,301	5,575 (-12%)	6,605 (+18%)	7,494 (+13%)	9,368 (+25%)
<b>Average remuneration on a full-time equivalent basis of employees (kSEK)<sup>4)</sup></b>					
Employees of the parent company	1,210	1,239 (+2.4%)	1,405 (+13.4%)	1,372 (-2.3%)	1,733 (+29%) <sup>5)</sup>

<sup>1)</sup> Total Remuneration as set out in column 5 of Table 1(1), including the value at vesting for multiple-year variable remuneration (vesting period of three years, 1 June 2021–1 June 2024), which had a higher outcome compared to 2023.

<sup>2)</sup> Total Remuneration as set out in column 5 of Table 1(2), including the value at vesting for multiple-year variable remuneration (vesting period of three years, 1 June 2021–1 June 2024), which had a higher outcome compared to 2023. The deputy CEO was allotted shares for the first time during 2021.

<sup>3)</sup> Alternative Performance Measures (APMs), see page 160 in the annual report 2024.

<sup>4)</sup> Excluding members of the group executive management per 31 December 2024.

<sup>5)</sup> Average remuneration for the Company's other employees includes the total remuneration, including the value at vesting for multiple-year variable remuneration (vesting period of three years, 1 June 2021–1 June 2024), which had a higher outcome compared to 2023. The one-year variable cash remuneration amount included in the table is preliminary related to the 2024 financial year which will be finally approved and paid during the spring of 2025.